sr141716 has been researched along with lenabasum in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burstein, SH; Tepper, MA; Zurier, RB | 1 |
| Cook, CD; Martin, BR; Vann, RE; Wiley, JL | 1 |
2 other study(ies) available for sr141716 and lenabasum
| Article | Year |
|---|---|
Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity.
Topics: Animals; Behavior, Animal; Binding Sites; Dose-Response Relationship, Drug; Dronabinol; Female; HL-60 Cells; Humans; Mice; Molecular Conformation; Pain Measurement; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Structure-Activity Relationship | 2014 |
Cannabimimetic properties of ajulemic acid.
Topics: Analgesics; Animals; Discrimination Learning; Dose-Response Relationship, Drug; Dronabinol; Male; Mice; Mice, Inbred ICR; Piperidines; Pyrazoles; Rats; Rats, Long-Evans; Receptor, Cannabinoid, CB1; Rimonabant | 2007 |